Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Reynolds

Showing results (141-150 of 212) with videos related to

Pageof 22
Sort By:
Pediatric Blood & Cancer|October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park, Judith G Villablanca, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complexBarry J Maurer, Ondrej Kalous, David W Yesair, et al.
Pediatric Blood & Cancer|August 27, 2010
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing programHernan Carol, Christopher L Morton, Richard Gorlick, et al.
Pediatric Blood & Cancer|August 20, 2013
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing ProgramRichard Gorlick, E Anders Kolb, Stephen T Keir, et al.
Pediatric Blood & Cancer|November 20, 2014
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|February 22, 2011
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programPeter J Houghton, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|May 18, 2011
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing programRichard B Lock, Hernan Carol, Christopher L Morton, et al.
Pediatric Blood & Cancer|January 11, 2013
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing ProgramRichard B Lock, Hernan Carol, John M Maris, et al.
Nature Genetics|December 4, 2012
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastomaMark Sausen, Rebecca J Leary, Siân Jones, et al.
Pediatric Blood & Cancer|May 4, 2011
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing programMin H Kang, C Patrick Reynolds, Peter J Houghton, et al.
Pageof 22

Showing results (141-150 of 212) with videos related to

Sort By:
Pageof 22
Pediatric Blood & Cancer|October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park, Judith G Villablanca, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complexBarry J Maurer, Ondrej Kalous, David W Yesair, et al.
Pediatric Blood & Cancer|August 27, 2010
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing programHernan Carol, Christopher L Morton, Richard Gorlick, et al.
Pediatric Blood & Cancer|August 20, 2013
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing ProgramRichard Gorlick, E Anders Kolb, Stephen T Keir, et al.
Pediatric Blood & Cancer|November 20, 2014
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|February 22, 2011
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programPeter J Houghton, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|May 18, 2011
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing programRichard B Lock, Hernan Carol, Christopher L Morton, et al.
Pediatric Blood & Cancer|January 11, 2013
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing ProgramRichard B Lock, Hernan Carol, John M Maris, et al.
Nature Genetics|December 4, 2012
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastomaMark Sausen, Rebecca J Leary, Siân Jones, et al.
Pediatric Blood & Cancer|May 4, 2011
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing programMin H Kang, C Patrick Reynolds, Peter J Houghton, et al.
Pageof 22